ReviewAnnals of the rheumatic diseases2005
Psoriasis pathophysiology: current concepts of pathogenesis.
Review in Annals of the rheumatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 4 syntheses or guidelines pooled it, 521 citations in OpenAlex.
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions: A Health Technology Assessment.Ontario health technology assessment series · 2020Pooled it
- Meta-analysis of NOD2/CARD15 polymorphisms with psoriasis and psoriatic arthritis.Rheumatology international · 2012Pooled it
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.Journal of the American Academy of Dermatology · 2008Guideline
- First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.British journal of clinical pharmacology · 2017Trial
- Trial
- The Immunological Intersection of Psoriasis and Autoimmune Diseases: Shared Pathways and Clinical Implications.Life (Basel, Switzerland) · 2026Review
- Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.Frontiers in immunology · 2026Review
- Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis.World journal of clinical cases · 2025Article
- Coexistence of Psoriasis and Pemphigus: A Case Report of Pemphigus Vulgaris With a Review of the Literature.Clinical case reports · 2025Article
- Bioinformatics and experimental approach identify DNMT3A as a diagnostic marker associated with regulated cell death patterns in psoriasis.Journal, genetic engineering & biotechnology · 2025Article
- Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise.Inflammopharmacology · 2025Review
- Evaluation of Atherogenic Indexes in Patients With Lichen Planopilaris: A Case-Control Study.Cureus · 2025Article
- Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease?World journal of hepatology · 2025Review
- Pharmacotherapy of arterial hypertension in patients with psoriasis.Journal of hypertension · 2025Review
- Exploring the Relationship Between Psychiatric Illness and Dermatological Disorders: A Narrative Review.Cureus · 2025Review
- A Mini-Review on the Symptoms and Pathogenesis of Psoriasis and Recent Nanotechnological Developments in its Treatment Strategies.Current pharmaceutical design · 2025Review
- Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.Advances in rheumatology (London, England) · 2024Review
- Genomic Profiling of the Overlap Phenotype between Psoriasis and Atopic Dermatitis.The Journal of investigative dermatology · 2024Article
- Regulation of epidermal barrier function and pathogenesis of psoriasis by serine protease inhibitors.Frontiers in immunology · 2024Review
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis vulgaris is a common skin disorder characterised by focal formation of inflamed, raised plaques that constantly shed scales derived from excessive growth of skin epithelial cells. The disease is defined by a series of linked cellular changes in the skin: hyperplasia of epidermal keratinocytes, vascular hyperplasia and ectasia, and infiltration of T lymphocytes, neutrophils, and other types of leucocyte in affected skin. In a relatively short period, psoriasis vulgaris has been conceptualised as a T lymphocyte mediated autoimmune disease and new biological therapies that target T cells have just entered routine clinical practice. Similarly, rapid progress has been made towards dissecting cellular and molecular pathways of inflammation that contribute to disease pathogenesis. This short review presents current pathogenic concepts that have emerged from genetic, genomic, and cellular information obtained in basic studies and from clinical studies of selective immune targeting drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.